Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Gland Pharma's Other Operating Expense for the
three
months ended in Mar. 2026 was ₹7,471 Mil.
Its Other Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was ₹29,818 Mil.
Gland Pharma's quarterly Other Operating Expense
increased
from Sep. 2025 (₹7,255 Mil) to Dec. 2025 (₹7,915 Mil) but then
declined
from Dec. 2025 (₹7,915 Mil) to Mar. 2026 (₹7,471 Mil).
Gland Pharma's annual Other Operating Expense
increased
from Mar. 2024 (₹22,706 Mil) to Mar. 2025 (₹24,607 Mil) and
increased
from Mar. 2025 (₹24,607 Mil) to Mar. 2026 (₹29,818 Mil).
Gland Pharma Other Operating Expense Related Terms
Gland Pharma Other Operating Expense Historical Data
* Premium members only.
The historical data trend for Gland Pharma's Other Operating Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)
Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.
Other Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹29,818 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Other Operating Expense of ₹29,818 Mil mean?
Gland Pharma (NSE:GLAND) has a Other Operating Expense of ₹29,818 Mil as of Mar. 2026. Other operating expenses that a company records on its income statement. View historical data on Gland Pharma and its competitors.
Is Gland Pharma's Other Operating Expense too high?
Gland Pharma's current Other Operating Expense is ₹29,818 Mil. Overall, Gland Pharma has a GF Score™ of 84/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Gland Pharma's Other Operating Expense compare to ZTS and UTHR?
Gland Pharma's Other Operating Expense of ₹29,818 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Operating Expense for a Drug Manufacturers company?
A good Other Operating Expense depends on the Drug Manufacturers industry context. However, Other Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Operating Expense mean?
A high Other Operating Expense can signal that a stock is expensive relative to its fundamentals. Other operating expenses that a company records on its income statement. View historical data on Gland Pharma and its competitors. Gland Pharma's current Other Operating Expense is ₹29,818 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gland Pharma stock overvalued right now?
Based on GuruFocus' analysis, Gland Pharma (NSE:GLAND) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹2,142.48, compared to a current price of ₹2,449.00 — trading 14.3% above its estimated fair value. The current Other Operating Expense is ₹29,818 Mil. Gland Pharma's overall GF Score™ is 84/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Operating Expense calculated?
Other Operating Expense is calculated from a company's financial statements. For Gland Pharma (NSE:GLAND), the current Other Operating Expense is ₹29,818 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gland Pharma (NSE:GLAND) Overvalued in 2026?
Based on GuruFocus' analysis, Gland Pharma stock appears to be overvalued.
The current stock price of ₹2,449.00 is trading 14.3% above its estimated GF Value™ of ₹2,142.48.
GuruFocus considers Gland Pharma to be Modestly Overvalued.
Key valuation signals for NSE:GLAND:
Other Operating Expense: ₹29,818 Mil
GF Value™: ₹2,142.48 vs. price of ₹2,449.00 (14.3% above fair value)
No single metric tells the full story. See the NSE:GLAND stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gland Pharma Ltd is engaged in the development, manufacturing, and marketing of complex injectables. The company's key molecules include Heparin Sodium Injection, Enoxaparin Sodium Injection, Rocuronium Bromide Injection, and Daptomycin Injection, among others. The group is also involved in a vast range of therapeutic categories, including Anti-Infectives, Anesthetics, Anti-Coagulants and their Antidotes, Anti-Malarials, Cardiology, and more, to Hormones and related Drugs, Fertility Supplements, and GnRH Agonists and Antagonists. Geographically, it derives a majority of revenue from the USA, and the rest from Europe, India, Canada, Australia, and other regions.
84GF Score
Get the complete analysis for NSE:GLAND
Other Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:GLAND has been successfully added to your 
